Moloney Kelley J, Mercado Jennifer U, Ludlam William H, Mayberg Marc R
a Seattle Pituitary Center, Swedish Neuroscience Institute, Seattle, WA, USA.
c Seattle Pituitary Center, Swedish Neuroscience Institute, Seattle, WA, USA.
Expert Rev Endocrinol Metab. 2012 Sep;7(5):491-502. doi: 10.1586/eem.12.49.
Cushing's disease (CD) is a rare and debilitating condition resulting from extended exposure to excessive glucocorticoids caused by an adrenocorticotropic hormone-secreting pituitary adenoma. First-line treatment for most patients with CD is trans-sphenoidal adenomectomy. Postsurgical remission remains problematic; however, due to the difficulty of removing the tumor. Until recently, there were no approved medical treatments for Cushing's syndrome, but recent data on pasireotide (SOM230; a novel somatostatin analog) demonstrate restored hormone levels and improvements in quality of life, with a safety profile similar to that of other somatostatin analogs, except for incidence of hyperglycemia. Pasireotide represents an exciting, novel, pituitary-targeted medical therapy for patients with CD who are not surgical candidates, or for those who experience postsurgical recurrence.
库欣病（CD）是一种罕见且使人衰弱的病症，由促肾上腺皮质激素分泌型垂体腺瘤导致长期暴露于过量糖皮质激素引起。大多数库欣病患者的一线治疗方法是经蝶窦腺瘤切除术。然而，由于肿瘤切除困难，术后缓解仍然存在问题。直到最近，库欣综合征还没有获批的药物治疗方法，但关于帕瑞肽（SOM230；一种新型生长抑素类似物）的最新数据表明，其能使激素水平恢复正常并改善生活质量，除高血糖发生率外，其安全性与其他生长抑素类似物相似。帕瑞肽为不适于手术的库欣病患者或术后复发患者提供了一种令人振奋的、新型的、针对垂体的药物治疗方法。
